Indeed, in this study, MYD88 inhibitor treatment stopped the progression of alveolar bone loss induced by Pg. Ultimately, osteocyte-specific drug delivery systems would need to be developed because systemic MYD88 inhibition will increase the host’s susceptibility to bacterial infection and impair bacterial clearance by the host immune system76–78. The gene discussed is JUP; the disease is bacterial infectious disease.